Kynurenine

Overview

Kynurenine is the primary metabolite of the kynurenine pathway, which handles ~95% of tryptophan catabolism in the body. While serotonin gets more attention, the kynurenine pathway is quantitatively dominant — and its downstream metabolites span the range from neuroprotective to neurotoxic. The pathway's rate-limiting enzymes (IDO1, IDO2, TDO) all require heme iron, creating a direct link between metal biology and neuroimmune signaling.

In the WikiBiome context, the kynurenine pathway is the mechanistic bridge between inflammation, metal dyshomeostasis, and neuropsychiatric disease: metal-driven inflammation upregulates IDO1, shunting tryptophan from serotonin to kynurenine, generating neurotoxic quinolinic acid that itself chelates iron and catalyzes fenton chemistry — a self-amplifying cycle.

The Kynurenine Pathway

``` Tryptophan │ ├──[IDO1/IDO2 (heme iron; IFN-gamma-inducible)]──→ Kynurenine │ │ └──[TDO (heme iron; liver, constitutive)]──────────────┘ │ ┌──────────────────────────────┤ │ │ Kynurenic acid (KA) 3-Hydroxykynurenine (3-HK) [neuroprotective] [neurotoxic] [NMDA antagonist] [generates free radicals] │ Quinolinic acid (QUIN) [potent neurotoxin] [NMDA agonist, excitotoxin] [chelates iron → Fenton] ```

Key Metabolites

MetaboliteFunctionClinical Relevance
Kynurenineahr ligand; immune modulatorElevated in inflammation; AhR activation supports Treg differentiation
Kynurenic acid (KA)Neuroprotective; NMDA receptor antagonistDepleted in ASD (q=0.02); protective against excitotoxicity
3-Hydroxykynurenine (3-HK)Neurotoxic; generates free radicalsElevated in neuroinflammation
Quinolinic acid (QUIN)Potent neurotoxin; NMDA agonist; excitotoxinElevated in MS relapses; chelates iron and catalyzes Fenton chemistry

The KA/QUIN Ratio

The balance between kynurenic acid (neuroprotective) and quinolinic acid (neurotoxic) determines net neurological impact. Inflammation shifts the pathway toward QUIN by upregulating enzymes in the neurotoxic branch.

Iron Dependency and Metal Connections

IDO1 and TDO Require Heme Iron

Both rate-limiting enzymes contain heme iron in their active sites. This creates multiple metal-kynurenine interactions:

  • Iron deficiency may impair IDO1/TDO activity, paradoxically reducing kynurenine production.
  • Iron excess supports IDO1 activity during inflammation, amplifying tryptophan diversion.
  • Metal-induced inflammation (via NF-kB, TLR4) upregulates IFN-gamma, which induces IDO1, systematically shifting the pathway toward neurotoxic outputs novikova 2025 microbiome derived metabolites parkinsons thesis.

Quinolinic Acid Chelates Iron

QUIN binds iron and forms QUIN-Fe complexes that catalyze Fenton chemistry, generating hydroxyl radicals in neural tissue novikova 2025 microbiome derived metabolites parkinsons thesis. This is a direct metal-neuroinflammation link: the kynurenine pathway not only responds to metal-driven inflammation but actively amplifies iron toxicity through its end product.

Microbiome Modulation

IDO1 Regulated by SCFAs

butyrate and other SCFAs modulate IDO1 expression, linking SCFA-producing commensal health to kynurenine pathway regulation mohsen 2025 ms gut microbiome immune interaction. Dysbiosis-driven SCFA depletion removes this brake on IDO1.

3-IAld Competes with Kynurenine for AhR

3-Indolealdehyde (3-IAld), produced by lactobacillus species, competes with L-kynurenine for AhR binding and tips tryptophan metabolism toward serotonin production via TPH1 induction zelante 2024 microbial ahr ligand 3iald tolerogenic ms. Loss of Lactobacillus (common in dysbiosis) removes this competition, allowing kynurenine to dominate AhR signaling.

Immune Tolerance

The kynurenine pathway supports Treg differentiation and immune tolerance via AhR activation. Impairment of this pathway (as observed in long covid and ME/CFS) favors Th17 dominance and autoimmunity saito 2024 metabolomic immune alterations long covid cfs.

Conditions Associated

ConditionKynurenine Pathway AlterationSource
depressionElevated kynurenine/tryptophan ratio (p=0.008)capuco 2020 gut microbiome dysbiosis depression review
autism spectrum disorderKynurenate significantly depleted (q=0.02)aziz zadeh 2025 brain activity tryptophan gut metabolites asd
multiple sclerosisQUIN elevated during relapses; IDO modulated by SCFAsmohsen 2025 ms gut microbiome immune interaction
parkinsons diseaseTryptophan diverted to kynurenine; QUIN-iron Fentonnovikova 2025 microbiome derived metabolites parkinsons thesis
long covid / ME/CFSReduced kynurenine products; impaired AhR signaling; Treg failuresaito 2024 metabolomic immune alterations long covid cfs
schizophreniaFMT from SCZ patients altered kyn catabolism in micetheleritis 2024 gut dysbiosis first episode psychosis review
cerebral palsyReduced tryptophan pool consistent with kyn/serotonin depletionwang 2023 amino acid metabolomics cerebral palsy plasma
fibromyalgiaAltered kynurenine pathway in FM-IBS overlap
postpartum depressionIDO1 induction during postpartum inflammation

Cross-References